###begin article-title 0
###xml 106 122 103 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cyclooxygenase 2</italic>
Functional role of NF-IL6beta and its sumoylation and acetylation modifications in promoter activation of cyclooxygenase 2 gene
###end article-title 0
###begin p 1
###xml 606 645 606 645 <email xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">journals.permissions@oxfordjournals.org</email>
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
###end p 1
###begin p 2
###xml 115 120 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 156 160 153 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAPK</sup>
###xml 284 289 275 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 487 492 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 505 513 493 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 615 620 603 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 707 712 695 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 775 780 760 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 843 850 825 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 856 864 838 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 967 975 943 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1074 1079 1044 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1131 1138 1098 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 1236 1241 1200 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1435 1440 1396 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
NF-IL6beta regulates gene expression and plays function roles in many tissues. The EGF-regulated cyclooxygenase-2 (cox-2) expression is mediated through p38MAPK signaling pathway and positively correlates with NF-IL6beta expression in A431 cells. NF-IL6beta coordinated with c-Jun on cox-2 transcriptional activation by reporter and small interfering RNA assays. NF-IL6beta could directly bind to CCAAT/enhancer-binding protein (C/EBP) and cyclic AMP-response element (CRE) sites of the cox-2 promoter by in vitro-DNA binding assay. The C/EBP site was important for basal and, to a lesser extent, for EGF-regulated cox-2 transcription, while the CRE site was a more specific response to EGF inducibility of cox-2 gene. SUMO1 expression attenuated EGF- and NF-IL6beta-induced cox-2 promoter activities. NF-IL6beta was found to be sumoylated by in vivo- and in vitro-sumoylation assays, and the SUMO1-NF-IL6beta (suNF-IL6beta) lost its ability to interact with p300 in in vitro-binding assay. NF-IL6beta was also acetylated by p300, and acetylation of NF-IL6beta enhanced the cox-2 promoter activity stimulated by NF-IL6beta itself. In vivo-DNA binding assay demonstrated that EGF stimulated the recruitment of p300 and NF-IL6beta to the cox-2 promoter, yet promoted the dissociation of SUMO1-modificated proteins from the promoter. These results indicated that NF-IL6beta plays a pivotal role in the regulation of basal and EGF-induced cox-2 transcription.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 377 378 377 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 527 528 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 529 530 526 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 544 545 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 555 556 548 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 590 591 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 601 602 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 634 635 627 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 636 637 629 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 700 705 693 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1006 1008 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 1035 1040 1020 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1066 1071 1051 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1156 1158 1137 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 1175 1177 1156 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 1178 1180 1159 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 1195 1197 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 1206 1208 1183 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 1209 1211 1186 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 1212 1214 1189 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 1257 1258 1234 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 1259 1261 1236 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 1294 1299 1271 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1423 1428 1400 1405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1512 1515 1489 1492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 694 699 <span type="species:ncbi:9606">Human</span>
###xml 1029 1034 <span type="species:ncbi:9606">human</span>
Prostaglandins play important roles in many biological processes, including cell division, immune responses, blood pressure regulation, ovulation, bone development and wound healing. The cyclooxygenase (COX, prostaglandin endoperoxide synthase) is a key enzyme in prostaglandin, prostacyclin and thromboxane biosynthesis from arachidonic acid. Two COX isoforms were described (1). COX-1 is constitutively expressed in most tissues and cells in animal species. COX-2 is induced by a wide-range of stimulators, such as IL-1beta (2,3), TNF-alpha (4), IL-18 (2), epidermal growth factor (EGF) (5) or LPS (6), in many distinct cell types (7-9) and is regulated mainly at the level of transcription. Human cox-2 promoter region contains a twin arginine translocation A and multiple regulatory elements, including two putative nuclear factor-kappaB (NF-kappaB) binding sites, one nuclear factor interleukin-6 (NF-IL6)/CCAAT/enhancer-binding protein (C/EBP) binding site and one cyclic AMP-response element (CRE) (10). Recent studies on human cox-2 promoter have shown that cox-2 transcription is regulated by different transcription factors, including NF-kappaB (11), NF-IL6/C/EBP (11-14), C/EBPdelta (12), CREB (12,13,15) and activation protein 1 complex (AP-1) (5,11), supporting that regulation of cox-2 gene expression could involve complex interactions among diverse transcription factors. Thus, transcriptional mechanism of cox-2 induction relies on cell type-specific as well as combined interactions of several cis-acting regulatory elements, transcription factors and signal transduction pathways.
###end p 4
###begin p 5
###xml 438 443 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 450 452 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 549 554 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 498 503 <span type="species:ncbi:9606">human</span>
The C/EBP family contains three main activating members, C/EBPalpha, C/EBPbeta and C/EBPdelta, that recognize the same DNA sequence. These three members have a common structure: an N-terminal domain bearing the transaction domain, a basic DNA-binding domain and a C-terminal leucine zipper domain that allows the homo- or hetero-dimerization of these factors. C/EBPdelta is involved in the ligand-stimulated transcriptional regulation of cox-2 gene (12). However, the detail molecular mechanism of human C/EBPdelta, NF-IL6beta, in the regulation of cox-2 gene transcription is unclear.
###end p 5
###begin p 6
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 800 802 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 904 909 898 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 912 914 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 1072 1074 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
Post-translational modification of proteins by sumoylation is an important regulatory mechanism and has been found to be utilized in many cellular processes (16-18). SUMO modification of several transcription factors has been reported, including the androgen receptor (19), LEF1 (20), c-Myb (21), TEL (22), Sp3 (23,24), p53 (25), c-Jun (26) and C/EBPs (26). SUMO conjugation has been shown to regulate several different protein functions including protein stability, subcellular localization and transcriptional activation regulation (18,27,28). The consensus sequence, (I/L)KXE, for sumoylation has been defined (29). The C/EBP family belongs to the large family of basic leucine zipper (bZIP) transcription factors. The repression domain I of C/EBPepsilon was demonstrated to be modified by SUMO1 (26), and this modification was proposed to be important for the inhibitory function of this domain. Kim et al. (25) also reported that conserved SUMO target sequences are present in C/EBPalpha, C/EBPbeta and C/EBPdelta, and that these isoforms can be conjugated to SUMO1 (26). However, the function of sumoylated C/EBPs is largely unknown, especially in the case of NF-IL6beta.
###end p 6
###begin p 7
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
Coactivator p300 and CREB-binding protein (CBP) serve as an integrator for gene transcription. Several reports have suggested involvement of p300 coactivator in cox-2 transcriptional regulation (4,5,30). p300 contains histone acetyltransferase (HAT) activity that modulates the acetylation of histones or transcription factors, thus affecting the DNA binding and transcriptional activation. p300 and CBP have been shown to participate in C/EBPs-mediated gene transcription (31-33). C/EBP family members trigger the phosphorylation of p300 and consequently increase p300-mediated transcriptional activation (34).
###end p 7
###begin p 8
###xml 69 74 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 92 94 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 95 97 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 134 139 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 273 278 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 320 322 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 323 325 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 326 328 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 414 419 400 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 432 433 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 563 565 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 667 672 647 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 916 921 890 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 997 1002 968 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1092 1097 1057 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 524 529 <span type="species:ncbi:9606">human</span>
Several reports have shown C/EBPbeta and C/EBPdelta's involvement in cox-2 gene expression (35,36). However, the effects of C/EBPs on cox-2 transcription are dependent on cell type and stage of differentiation. Gain or loss of function of C/EBPdelta and C/EBPbeta regulate cox-2 promoter activity in various cell types (35,37,38). In our previous study, we found that induction of c-Jun is involved in EGF-induced cox-2 expression (5). In addition, we found that the level of NF-IL6beta is also elevated by EGF treatment in human epidermoid carcinoma A431 cells (37). In this study, we extended our work to investigate the functional role of NF-IL6beta in regulating cox-2 promoter activity in the basal and EGF-induced transcriptional state, and the effects that sumoylation and acetylation of NF-IL6beta play function roles on the promoter. Our results indicated that NF-IL6beta mediates the basal and EGF-induced cox-2 promoter state, and sumoylation of NF-IL6beta attenuates the activation of cox-2 promoter, while p300 can acetylate NF-IL6beta and participate in the NF-IL6beta-enhanced cox-2 promoter regulation.
###end p 8
###begin title 9
MATERIALS AND METHODS
###end title 9
###begin title 10
Materials
###end title 10
###begin p 11
###xml 787 795 776 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 1001 1009 990 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sliencer</italic>
###xml 1481 1484 1452 1453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 1495 1498 1464 1465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 643 649 <span type="species:ncbi:9913">bovine</span>
###xml 1676 1681 <span type="species:ncbi:9606">human</span>
Human EGF was purchased from Peprotech (Rocky Hill, NJ). SB203580 was obtained from Calbiochem (San Diego, CA). Antibodies against COX-2, NF-IL6beta, SUMO1 and alpha-p300-conjugated agarose were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against acetyl-lysine were purchased from Upstate (Charlottesville, VA). Monoclonal alpha-HA antibody was purchased from BM (Boehringer, Mannheim, Germany). Lipofectamine 2000, Dulbeco's modified Eagle's medium (DMEM), SuperScriptTM III and Opti-MEM medium were obtained from Invitrogen (Carlsbad, CA). All oligonucleotides were synthesized by MDBio Inc. (Taipei, Taiwan). Fetal bovine serum (FBS) was from HyClone Laboratories (Logan, UT). Streptavidin-Sepharose beads were purchased from Amersham Biosciences (Buck, UK). In vitro transcription/translation kit was purchased from Promega (Madison, WI). Expression plasmid pcDNA3/HA was a gift of Dr. Hsin-Fang Yang-Yen (Institute of Molecular Biology, Academia Sinica, Tapei, Taiwan). pSliencertrade mark 3.0 vector was purchased from Ambion (Austin, TX). The sumoylation kit was purchased from LAE Biotechnology Co. (Taichung, Taiwan). The recombinant p300 protein was purchased from Active Motif (Carlsbad, CA). The cloning vector, yTA vector, was purchased from Yeastern Biotech. Co. (Taipei, Taiwan). DNA polymerase kit and BD Advantage GCtrade mark PCR kit for PCR-cloning were purchased from BD Biosciences (Palo Alto, CA). Protein concentration column, Amicon(R) Centriprep(R) Filter Devices, was purchased from MILLIPORE (Billerica, MA). All other reagents used were of the highest purity obtainable. The expression vector TAM-67 encoding the truncated human c-Jun was the generous gift of Dr M. Birrer (NCI, National Institutes of Health, Rockville, MD). Small interfering RNA (siRNA) pool for c-Jun and a non-specific control siRNA were purchased from Darmacon (Lafayette, CO). pSUPERc-Jun siRNA was designed and constructed by KRII International Co. (Taipei, Taiwan).
###end p 11
###begin title 12
Plasmid transfection and reporter gene assay
###end title 12
###begin p 13
###xml 1068 1070 1060 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
A431 and HeLa cells were maintained in DMEM supplemented with 10% FBS, 100 microg/ml streptomycin, and 100 U/ml penicillin. All EGF treatments of A431 cells were in the concentration of 50 ng/ml. Cells were transfected with plasmids by lipofection using Lipofectamine 2000 according to the manufacturer's instruction. Cells were replated 24 h before transfection at an optional density in 3 ml of fresh culture medium in a 3.5 cm plastic dish. For usage in transfection, 5 microl of Lipofectamine 2000 were incubated with reporter plasmid and the expression plasmids as indicated in each experiment, in 2 ml of Opti-MEM medium for 30 min at room temperature. Total DNA concentration for each experiment was matched with empty vector. Cells were transfected by changing the medium with 2 ml of Opti-MEM medium containing the plasmids and Lipofectamine 2000, unless otherwise stated. Cells were stimulated with EGF when necessary and incubated for 16 h. The luciferase activities in cell lysates were measured by the luciferase assay system and determined as described (37). Luciferase activity was normalized per microgram of extract protein.
###end p 13
###begin title 14
Small interfering RNAs assay
###end title 14
###begin p 15
###xml 471 479 471 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sliencer</italic>
###xml 585 593 573 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sliencer</italic>
###xml 706 711 <span type="species:ncbi:9606">human</span>
Two oligonucleotides were synthesized according to the oligonucleotide design procedure described in the Ambion's manual. They were as follows: 5'-gATCCgCCAggAgATgCAgCAgAAgTTCAAgAgACTTCTgCTgCATCTCCTggTTTTTTggAAA-3' and 5'-AgCTTTTCCAAAAAACCAggAgATgCAgCAgAAgTCTCTTgAACTTCTgCTgCATCTCCTggCg-3'. The 5' ends of the two oligonucleotides were non-complementary and formed the BamHI and HindIII restriction site overhangs that facilitated efficient directional cloning into the pSliencertrade mark 3.0 vector. Cell transfection separately with NF-IL6beta siRNA expression vectors (pSi-1) and pSliencertrade mark 3.0 negative control vectors (pSi-C), which encode a hairpin siRNA whose sequence is not found in the human genome databases was purchased from Ambion, were carried out by Lipofectamine 2000 or lipofectin according to the manufacturer's instruction. After 24 h recovery in complete medium, RT-PCR or western blotting assay was performed from the transfectants, which had been previously starved for 6 h and re-stimulated with EGF for 2 h.
###end p 15
###begin title 16
DNA affinity precipitation assay
###end title 16
###begin p 17
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 510 511 494 495 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 513 514 497 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
Nuclear extracts from A431 cells with or without EGF treatment were prepared, and DNA affinity precipitation assay was performed according to the method described previously (38,39). The 200 microg of lysates extracted from each group were incubated with 1 microg of biotinylated C/EBP or CRE oligonucleotides in the presence of DNA binding buffer containing 10 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM DTT, 1 mM EDTA, 10% (v/v) glycerol, 10 mM NaF, 1 mM PMSF, 1 microg aprotinin/ml, 1 microg leupeptin/ml, 1 mM Na3VO4 and 2 microg poly(dI-dC). After 1 h of incubation at 4degreesC, 40 microl of streptavidin-Sepharose were added to the reaction mixture and the incubation was continued for 1 h. The complexes were then precipitated by centrifugation and washed three times with DNA binding buffer before they were resolved by SDS-PAGE and subsequently analysed by immunoblotting with alpha-C/EBPdelta antibodies.
###end p 17
###begin title 18
Chromatin immunoprecipitation assay
###end title 18
###begin p 19
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">40</xref>
###xml 586 591 577 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 422 428 <span type="species:ncbi:9986">rabbit</span>
The chromatin immunoprecipitation (ChIP) assay was carried out essentially as described by Saccani et al. (40). Briefly, A431 cells with or without prior stimulation with EGF were treated with 1% formaldehyde for 15 min. The cross-linked chromatin was then prepared and sonicated to an average size of 300-500 bp. The DNA fragments were immunoprecipitated with antibodies specific to p300, SUMO1 and NF-IL6beta or control rabbit IgG at 4degreesC, overnight. After reversal of cross-linking, the immunoprecipitated chromatin was amplified by PCR amplification of specific regions of the cox-2 genomic locus. The primers were as follows: COX-2/F-186: 5'-CTGGGTTTCCGATTTTCTCA-3', COX-2/R+49; 5'-GAGTTCCTGGACGTGCTCCT-3', COX-2/F+800; 5'-CTAAGGCAGGTTAAAAAATTGTATTTCC-3' and COX-2/R+1200: 5'-TCCCTTGAAGTGGGTAAGTATGTAGTG-3'. The amplified DNA products were resolved by agarose gel electrophoresis and confirmed by sequencing.
###end p 19
###begin title 20
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro expression of NF-IL6beta proteins
###end title 20
###begin p 21
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 782 785 751 752 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 796 799 763 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 108 113 <span type="species:ncbi:4565">wheat</span>
In vitro transcription/translation of NF-IL6beta was performed using 1 microg of pcDNA3-HA/NF-IL6beta and a wheat germ coupled transcription/translation system according to the instructions provided by the manufacturer. Recombinant His-tagged NF-IL6beta (His/NF-IL6beta) and NF-IL6betaK120A (His/NF-IL6betaK120A) were generated from the pET-28a (+) vector. The recombinant plasmids were transformed into BL21 (DE3) cells. Isopropyl-beta-D-thiogalactopyranoside (IPTG) was used to induce recombinant protein expression in the transformants. His/NF-IL6beta and His/NF-IL6betaK120A were purified according to the instructions provided by the manufacturer and dialysed with dialysis buffer (50 mM HEPES pH7.4, 100 mM NaCl and 1 mM DTT). The dialysed proteins were concentrated by Amicon(R) Centriprep(R) Filter Devices.
###end p 21
###begin title 22
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
In vitro- and in vivo-SUMO modification assays
###end title 22
###begin p 23
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 268 269 245 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 335 343 300 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 582 589 534 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 978 979 927 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
In vitro-SUMO modification of NF-IL6beta was performed using sumoylation kit. Briefly, assays were performed with 2 microl of SAEI and SAEII (7.5 microg/ml), 2 microl of UBC9 (50 microg/ml), 2 microl of 10x sumoylation reaction buffer (200 mM HEPES, pH 7.5, 50 mM MgCl2 and 20 mM ATP), 2 microl of SUMO1 (50 microg/ml) and 2 microl of in vitro-translated HA/NF-IL6beta. The reaction mixture was incubated at 37degreesC for 30 min and then quenched with SDS-PAGE sample buffer. The samples were subsequently analysed by SDS-PAGE and immunoblotting analysis with alpha-HA antibodies. In vivo-sumoylation assay was carried out in A431 cells. Cells were transfected with pcDNA3-HA/NF-IL6beta expression vectors in the presence or absence of SUMO1-GG. Cell extracts were prepared in sample buffer (5% SDS, 0.15 M Tris-HCl pH 6.7 and 30% glycerol) and then diluted 1:3 with RIPA buffer (25 mM Tris-HCl pH 8.2, 50 mM NaCl, 0.5% NP-40, 0.5% deoxycholate and 0.1% SDS), containing 20 mM N-ethylmaleimide and 1 mM PMSF, 1 microg aprotinin/ml and 1 microg leupeptin/ml for subsequent immunoprecipitation assay.
###end p 23
###begin title 24
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
In vitro- and in vivo-acetylation assay
###end title 24
###begin p 25
###xml 393 400 369 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
Purified p300 protein (50 ng) and 0.5 microg of the indicated His/NF-IL6beta protein or His/NF-IL6betaK120 were incubated in a reaction mixture containing 50 mM Tris-HCl, pH 8.0, 10% glycerol, 0.1 mM EDTA, 1 mM DTT and 40 microM acetyl-coenzyme A for 1 h at 30degreesC. The reaction mixture was subjected to SDS-PAGE and analysed by western blotting using anti-alpha-acetyl-lysine antibodies. In vivo-acetylation assay was performed by transfecting cells with the pcDNA3-HA/NF-IL6beta expression vectors in the presence or absence of p300 expression plasmid. Cells were lysed in sample buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM EDTA and 1% Triton X-100) and then diluted 1:4 with TE buffer (10 mM Tris-HCl, pH 7.5 and 0.1 mM EDTA), containing 100 microM sodium butyrate, 1 mM PMSF, 1 microg aprotinin/ml and 1 microg of leupeptin/ml for immunoprecipitation assay.
###end p 25
###begin title 26
Construction of reporter plasmids and expression vectors
###end title 26
###begin p 27
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 1164 1169 1146 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1237 1238 1219 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 811 816 <span type="species:ncbi:9606">human</span>
The cox-2 promoter fragment from -207 to +49 bp (-207/+49wt) was obtained by PCR from the pXC918 reporter (5). The primers used were as follows: COX-2/KpnI-207: 5'-GGGGTACCTGCTCCCAAATTGGGGCAGC-3', COX-2/HindIII+49: 5'-GGAAGCTTGAGTTCCTGGACGTGCTCC-3'. The PCR fragments were cloned into yTA vector and verified by sequencing. A KpnI/HindIII fragment was subcloned into the multi-cloning sites of the promoter-less vector pGL2-basic. Mutant reporter plasmids were derived from -207/+49wt by site-directed mutagenesis of each individual region as indicated. Plasmid pGL2-promoter/COX-2/1XCEBP (pGL2-promoter 1XC/EBP) was derived by inserting one copy of the DNA fragment containing the C/EBP motif sequence (5'-GGGCTTACGCAATTTTTTTAA-3') into the SmaI site of the pGL2-promoter vector. NF-IL6beta was generated from human liver cDNA library by PCR using BD Advantage GCtrade mark PCR kit and using the following oligonucleotides: 5'-CGGGATCCAGCGCCGCGCTCTTCAGCCTG-3' and 5'-GGCCTCGAGGCCGCGCGTTACCGGCAGTC-3'. The amplified fragment was digested with BamHI and XhoI and inserted into BamHI- and XhoI-digested pcDNA3-HA to produce HA-tagged NF-IL6beta (HA/NF-IL6beta). The cox-2 promoter plasmids pXC80 and pXC918 have been described previously (5).
###end p 27
###begin title 28
RT-PCR
###end title 28
###begin p 29
Total RNA was isolated from A431 cells using the TRIzol RNA extraction kit. Of the isolated RNA 1 microg was subjected to reverse transcription with SuperScriptTM III. Specific primers for COX-2: 5'-CCCACTTCAAGGGATTTT-3' and 5'-CCAGACCAAAGACCTCCT-3', and for NF-IL6beta: 5'-AGCGCAACAACATCGCCGTG-3' and 5'-GTCGGGTCTGAGGTATGGGTC-3', were used for analyses. The PCR products were separated by electrophoresis in 1% agarose gel and visualized with ethidium bromide staining.
###end p 29
###begin title 30
p300 pull-down assay
###end title 30
###begin p 31
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro-translated HA/NF-IL6beta (2 microl) were incubated with purified p300 protein in a buffer composed of 50 mM Tris-HCl, pH 8.0, 10% glycerol, 0.1 mM EDTA and 1 mM DTT. After pulling down by alpha-p300-conjugated agarose (p300-AC), the immunoprecipitation pellets were washed and separated by SDS-PAGE for subsequent detection by immunoblotting with alpha-HA antibodies.
###end p 31
###begin title 32
RESULTS
###end title 32
###begin title 33
###xml 3 7 3 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAPK</sup>
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
p38MAPK inhibitor attenuates EGF-induced cox-2 transcription
###end title 33
###begin p 34
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 260 269 260 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1A</xref>
Recent studies have shown that the known C/EBP family proteins can modulate cox-2 gene expression through interactions with each other or other transcription factors. Hence prior to this study, we have verified the expression of C/EBPs in the presence of EGF (Figure 1A). According to these data, the expression pattern of C/EBPalpha is not affected by EGF treatment, whereas C/EBPbeta expression can be greatly increased by EGF treatment, but only after a 6 h delay. Otherwise, NF-IL6beta pre-existed before EGF treatment and enhanced by EGF treatment. The induction pattern of NF-IL6beta is similar with c-Jun and COX-2 expression patterns after EGF treatment.
###end p 34
###begin p 35
###xml 32 36 32 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAPK</sup>
###xml 80 90 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF-IL6&#946;</italic>
###xml 120 122 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 178 183 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 259 263 253 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAPK</sup>
###xml 279 295 273 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF-IL6&#946;/cox-2</italic>
###xml 387 397 378 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF-IL6&#946;</italic>
###xml 407 412 395 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 458 462 446 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAPK</sup>
###xml 512 521 500 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1B</xref>
###xml 611 616 596 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 642 646 627 631 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAPK</sup>
We previously found that the p38MAPK signaling pathway mediates the EGF-induced NF-IL6beta transcription in A431 cells (37). To examine the possibility that NF-IL6beta regulates cox-2 gene expression in A431 cells, we first studied the correlation between p38MAPK activation and NF-IL6beta/cox-2 gene transcription. RT-PCR assay was carried out for this study. The levels of EGF-induced NF-IL6beta mRNA and cox-2 mRNA were attenuated by pretreatment with p38MAPK inhibitor, SB203580, in a dose-dependent manner (Figure 1B). The results suggest a close relationship between EGF-induced NF-IL6beta expression and cox-2 transcription through p38MAPK signaling activation.
###end p 35
###begin title 36
###xml 38 43 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
NF-IL6beta plays a functional role in cox-2 promoter activity
###end title 36
###begin p 37
###xml 61 66 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 182 187 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 210 219 204 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2A</xref>
###xml 259 264 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
To address and connect whether NF-IL6beta would activate the cox-2 promoter, cells were cotransfected with an NF-IL6beta expression vector and a reporter construct controlled by the cox-2 promoter. As shown in Figure 2A, overexpression of NF-IL6beta enhanced cox-2 promoter activity in a dose-dependent manner. The effect could be enhanced by EGF treatment. The results suggest that NF-IL6beta might play a functional role in the basal and EGF-induced expression of COX-2.
###end p 37
###begin p 38
###xml 84 89 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 369 374 357 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 381 390 369 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2B</xref>
###xml 513 518 501 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 537 538 525 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 696 705 681 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2B</xref>
###xml 875 884 857 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2C</xref>
###xml 1009 1014 988 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1072 1073 1051 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 1074 1076 1053 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">41</xref>
###xml 1113 1118 1092 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1224 1233 1200 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2C</xref>
###xml 1317 1322 1290 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1376 1381 1349 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1573 1578 1540 1545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1589 1598 1556 1565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2D</xref>
###xml 1696 1701 1660 1665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
To investigate the effect of endogenous NF-IL6beta on transcriptional activation of cox-2 gene, complementary specific oligonucleotides aimed to inhibit NF-IL6beta gene expression by RNA interference were designed. Transfection of A431 cells with the NF-IL6beta siRNA expression vector resulted in reduction of EGF-induced NF-IL6beta mRNA and a concomitant decrease of cox-2 mRNA (Figure 2B, upper panel). Consistent with the RT-PCR results, cells cotransfected with a luciferase reporter construct controlled by cox-2 promoter, pXC918 (5), and an NF-IL6beta siRNA expression vectors, pSi-1, expressed significantly less luciferase activity than that cotransfection with negative control, pSi-C (Figure 2B, lower panel). Cotransfection of HA/NF-IL6beta expression vectors with pSi-C increased COX-2 expression, but the transfectant with pSi-1 decreased the COX-2 expression (Figure 2C). These results suggest that NF-IL6beta plays a role in regulating COX-2 expression. Since c-Jun is involved in EGF-induced cox-2 transcriptional activation through the CRE binding site (5,41), we examined whether activation of cox-2 promoter, which bears a CRE binding site, by NF-IL6beta requires the cooperation with c-Jun. As shown in Figure 2C, cells cotransfected with c-Jun siRNA expression vector reduced NF-IL6beta-induced cox-2 promoter activity, indicating that the activation of cox-2 promoter by NF-IL6beta is, at least in part, dependent on c-Jun. Furthermore, cotransfection of cells with c-Jun and NF-IL6beta expression vectors resulted in a synergistic activation of the cox-2 promoter (Figure 2D). Taken together, these data indicate that NF-IL6beta and c-Jun likely co-regulate EGF-dependent cox-2 expression.
###end p 38
###begin title 39
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
C/EBP and CRE motifs are important for cox-2 gene activation in A431 cells
###end title 39
###begin p 40
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 267 276 267 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3B</xref>
###xml 838 843 814 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 998 1003 974 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1149 1154 1119 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1210 1219 1180 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3C</xref>
###xml 1341 1346 1308 1313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1617 1622 1575 1580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1700 1705 1655 1660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1905 1914 1860 1869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3D</xref>
###xml 2019 2024 1971 1976 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
To further study whether C/EBP and CRE motifs are involved in the basal and EGF-induced cox-2 gene regulation, reporter expression controlled by the wild-type or mutant cox-2 gene promoter was assessed in transient transfection studies. The results are summarized in Figure 3B. A point mutation at the C/EBP motif resulted in 60-70% loss of the basal promoter activity, but only a 20-30% decrease in EGF-inducible increase of the promoter activity (compare -207/+49wt with -207/+49mCEBP). In contrast, a point mutation at the CRE motif lost approximately40% of the basal promoter activity and approximately45-55% of EGF-inducible activity (compare -207/+49wt with -207/+49mCRE). The stimulatory effect of EGF was abolished when both CRE and C/EBP sites were mutated (-207/+49mCE/C), suggesting that C/EBP and CRE motifs are essential for cox-2 promoter activity. These results demonstrate that CRE motif is more important in EGF response, while C/EBP site is more important in regulating the basal cox-2 expression. To evaluate the effect of NF-IL6beta on C/EBP and CRE motifs, the NF-IL6beta expression vector was cotransfected with various mutant cox-2 promoters in A431 cells. The results are summarized in Figure 3C. The mutation at C/EBP and CRE sites diminished 75 and 40%, respectively, of the stimulatory effect of NF-IL6beta on the cox-2 promoter (lanes 2 and 3). While the NF-IL6beta effect seems to be more prominent at the C/EBP motif, double mutation at both sites almost completely abolished the NF-IL6beta response (lane 4). Since NF-IL6beta played a functional role in the transcriptional activity of cox-2 promoter, we examined whether NF-IL6beta binds to the C/EBP or CRE motifs of cox-2 promoter. To test the binding activity between CRE and C/EBP motifs, DNA affinity precipitation assay was performed with nuclear extracts prepared from control and EGF-treated A431 cells. As seen in Figure 3D (lanes 5 and 8), EGF apparently increased the amount of NF-IL6beta bound to the C/EBP and CRE motifs of cox-2 promoter.
###end p 40
###begin title 41
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
Sumoylation plays a negative regulatory role in cox-2 promoter activation
###end title 41
###begin p 42
###xml 82 87 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 230 235 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 290 298 280 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 303 310 293 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 489 491 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 571 576 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 747 756 714 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4A</xref>
###xml 1184 1189 1148 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
Base on these results, we have verified that NF-IL6beta play a functional role in cox-2 transcription. We then tried to elucidate the mechanism in which NF-IL6beta modulates the basal and EGF-induced transcriptional regulation of cox-2 gene. C/EBPdelta was reported to be a SUMO1 substrate in vitro and in vivo, and a K120A mutant of the Gal4-C/EBPdelta(1-142) fusion protein lost approximately60% of its repressive activity, as compared with the wild-type Gal4-C/EBPdelta(1-142) protein (26). To investigate whether sumoylation acts on the transcription factors for the cox-2 promoter, transient reporter assay was performed. Cotransfection of the SUMO1 expression vector significantly repressed the NF-IL6beta-enhanced pXC918 reporter activity (Figure 4A, compare lanes 3 and 4 with lanes 5 and 6). To specifically examine whether the C/EBP-binding complex participated in the SUMO-mediated repressive effect, a heterologous reporter pGL2 promoter-C/EBP was used, and the NF-IL6beta-enhanced pGL2 promoter-C/EBP reporter activity could be attenuated by exogenously expressed SUMO1 (compare lanes 9 and 10 with lanes 11 and 12). These results suggest that sumoylation might suppress cox-2 promoter activity under the EGF-deprived condition, and that the C/EBP motif might be the site of SUMO-mediated effect.
###end p 42
###begin title 43
NF-IL6beta is a SUMO substrate
###end title 43
###begin p 44
###xml 387 395 367 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 479 487 459 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 589 597 563 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 599 608 573 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5A</xref>
###xml 900 902 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 1041 1050 1009 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5B</xref>
###xml 1113 1121 1081 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1385 1393 1347 1355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1603 1608 1556 1561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1619 1628 1572 1581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5C</xref>
###xml 1686 1695 1639 1648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5C</xref>
###xml 1973 1982 1917 1926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5C</xref>
###xml 2479 2488 2408 2417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5D</xref>
###xml 3005 3010 2904 2909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
###xml 85 90 <span type="species:ncbi:9606">human</span>
###xml 200 205 <span type="species:ncbi:10090">mouse</span>
Although the mouse C/EBPbeta has been shown to be a target for SUMO1, sumoylation of human C/EBPdelta (NF-IL6beta) and its biological function have not been elucidated. By sequence comparison between mouse C/EBPdelta and NF-IL6beta, the consensus sequence for SUMO attachment, LKREP, in the regulatory domain motif (RDM) was conserved. To examine whether NF-IL6beta is a SUMO substrate, in vitro-sumoylation assay was carried out with purified E1 (SAEI and SAEII), E2 (Ubc9) and in vitro-transcribed/translated HA/NF-IL6beta. SUMO1 or SUMO3 could be covalently conjugated to HA/NF-IL6beta in vitro (Figure 5A, lanes 3 and 4). To map the site of sumoylation, we first examined the sequence and found a region between amino acid 110 and 151 in HA/NF-IL6beta contained a potential sumoylation site (data not shown). The lysine 120 in this region has been reported to be a potential site of sumoylation (26). A K120A mutation was then generated by mutagenesis in HA/NF-IL6beta to see whether sumoylation of the protein was affected. As shown in Figure 5B (lane 4), the K120A mutant protein could not be sumoylated by in vitro-sumoylation assay, suggesting that lysine 120 is the site of sumoylation. Since post-translational modifications of transcription factor often affect their DNA binding, the DNA-binding activity of NF-IL6beta and suNF-IL6beta was examined by gel-shift assay using in vitro-translated HA/NF-IL6beta protein and labeled CRE or C/EBP probes. NF-IL6beta bound to DNA as a homodimer (our observation, data not shown). The homodimerized HA/NF-IL6beta could bind to the C/EBP motif at the cox-2 promoter (Figure 5C, lane 2). Interestingly, it also bound to the CRE motif (Figure 5C, lane 5), a result subsequently confirmed with purified His/NF-IL6beta protein (data not shown). Using equal amount of the proteins, we found no appreciable differences between HA/NF-IL6beta and sumoylated HA/NF-IL6beta, in term of DNA-binding and homodimerization activities (Figure 5C, compare lane 2 with lane 3, or lane 5 with lane 6). We next examined whether the turnover rates (half-life) of NF-IL6beta and NF-IL6betaK120A are different. Transfected cells were harvested at different time points post-cycloheximide treatment, and exogenously expressed HA/NF-IL6betawt or HA/NF-IL6betaK120A in cell lysates were analysed by western blotting. We measured the different time points of remained HA/NF-IL6beta proteins and separately normalize with the '0' time point. As shown in Figure 5D, the turnover half-life of HA/NF-IL6betawt was approximately3.5-4 h, similar to that of HA/NF-IL6betaK120A. There was also no appreciable difference in the patterns of nuclear localization between the wild-type and K120A mutant NF-IL6beta proteins (data not shown). These results suggest that NF-IL6betaK120A has the same DNA-binding activity, protein half-life and nuclear localization as NF-IL6betawt. We then moved on to address the issue of whether NF-IL6betaK120A is involved in the transactivation activity of cox-2 transcription.
###end p 44
###begin p 45
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 161 166 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 262 269 256 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 553 562 535 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6A</xref>
###xml 682 691 661 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6A</xref>
###xml 852 861 828 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6A</xref>
###xml 1033 1035 1001 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
###xml 1120 1122 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">43</xref>
###xml 1335 1344 1297 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6B</xref>
###xml 1662 1671 1615 1624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6C</xref>
###xml 1801 1806 1751 1756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 977 980 <span type="species:ncbi:9860">Elk</span>
The regulatory domain motif of C/EBPs is critical for inhibitory domain function (26). To test whether the SUMO-conjugated NF-IL6beta is important for silencing cox-2 transcription, we first examined whether NF-IL6beta is a sumoylated protein in A431 cells. The in vivo-sumoylation assay was performed by transfecting cells with expression vectors of SUMO1 active form and HA/NF-IL6beta or HA/NF-IL6betaK120A. western blotting analysis indicated that the suHA/NF-IL6beta was detectable in A431 cells. HA/NF-IL6beta was endogenously sumoylated in cells (Figure 6A, compare lane 1 with lane 3), and the sumoylated HA/NF-IL6beta was increased when cells were cotransfected with SUMO1 (Figure 6A, compare lane 3 with lane 4). However, the no SUMO-conjugated patterns were seen when HA/NF-IL6betaK120A was cotransfected with the SUMO1-GG expression vector (Figure 6A, compare lanes 3 and 4 with lanes 5 and 6). Sumoylation of proteins is agent-dependent. For example PMA can induce Elk-1, but not IkappaBalpha, sumoylation in COS7 cells (42). The constitutive sumoylation is also observed for STAT1 at the lysine703 residue (43). We therefore investigated whether EGF regulates SUMO1 conjugation to NF-IL6beta in A431 cells. Using immunoprecipitation and western analysis, we found EGF attenuated the content of suNF-IL6beta in A431 cells (Figure 6B, compare lane 1 with lane 2, and lane 3 with lane 4). Finally, the transactivation activity of NF-IL6betawt and NF-IL6betaK120A mutant was evaluated in co-transfection studies. The results indicate that the K120A mutant contributes higher reporter activities than the wild-type NF-IL6beta on the -207/+49wt reporter (Figure 6C, compare lanes 1 and 2 with lanes 5 and 6) suggesting that an intact lysine 120 of NF-IL6beta is necessary for the repression in cox-2 transcription.
###end p 45
###begin title 46
NF-IL6beta is a HAT (p300) substrate
###end title 46
###begin p 47
###xml 87 89 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
###xml 145 147 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 148 150 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 151 153 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 300 305 290 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 334 336 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">41</xref>
###xml 631 640 608 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7A</xref>
###xml 740 749 714 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7B</xref>
###xml 809 816 783 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 826 834 800 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1055 1064 1020 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7B</xref>
###xml 1418 1423 1368 1373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1443 1452 1393 1402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7C</xref>
###xml 1548 1553 1498 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1694 1699 1641 1646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1796 1805 1740 1749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7D</xref>
A previous study reported that PU.1 could enhance p300 mediated-C/EBPbeta acetylation (44). Although C/EBPs were reported to interact with p300 (31,33,45), no evidence to date suggests that NF-IL6beta is an acetylated protein including C/EBPdelta. To address this issue and verify that EGF regulates cox-2 transcription through p300 (41), we investigated whether acetylated NF-IL6beta (acNF-IL6beta) is detectable in A431 cells. Using alpha-acetyl-lysine antibodies, we were able to analyse immunoprecipitated products, from the cell lysates containing endogenous p300. We found that EGF enhanced the acetylation of HA/NF-IL6beta (Figure 7A, compare lanes 3 with 4). Furthermore, exogenously expressed p300-enhanced NF-IL6beta acetylation (Figure 7B, compare lanes 3 and 4 with lanes 5 and 6). To confirm our in vivo data, an in vitro-acetylation assay was performed using purified p300 with His/NF-IL6beta or His/NF-IL6betaK120A. Despite removing the acetylation site at lysine 120, p300 is still able to acetylate NF-IL6betaK120A at other unknown site (Figure 7B, compare lanes 3 with 5). To examine whether NF-IL6beta was involved in an increase in p300 transactivation activity, we perform a reporter assay by cotransfection of p300 and NF-IL6beta expression vectors with or without knockdown expression vectors of NF-IL6beta. The knockdown of exogenous expression of NF-IL6beta inhibited p300/NF-IL6beta-involved cox-2 reporter activity (Figure 7C). Additionally, to dissect whether K120A mutant participated in the p300 transaction activity, cox-2 reporter assay was carried out by combination of p300 with NF-IL6beta or K120A expression vectors. Exogenous p300 proteins exhibited higher cox-2 promoter/reporter activity regardless whether wild-type or K120A mutant of NF-IL6beta was used (Figure 7D, compare lanes 1 with 3 and lanes 2 with 4). These results suggest that NF-IL6beta is a HAT (p300) substrate and the position of lysine120 on NF-IL6beta is not absolutely critical for p300 action.
###end p 47
###begin title 48
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
SUMO1 represses p300-enhanced cox-2 promoter activity
###end title 48
###begin p 49
###xml 84 89 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 222 227 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 237 244 231 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 371 376 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 388 397 376 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8A</xref>
###xml 488 493 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 538 547 526 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8A</xref>
###xml 642 647 630 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 658 667 646 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8A</xref>
###xml 840 845 825 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
Our results proposed that NF-IL6beta acts as a bifunctional transcription factor on cox-2 gene suppression and activation by post-translational modification. To examine whether post-translated NF-IL6beta could bind to the cox-2 promoter in vivo, a ChIP assay was performed for NF-IL6beta, SUMO1 and p300. EGF treatment increased the level of binding of NF-IL6beta to the cox-2 promoter. (Figure 8A, compare lanes 3 with 4). The binding activity of SUMO1-modified proteins was abundant on cox-2 promoter but decreased after EGF treatment (Figure 8A, compare lanes 5 with 6). Lastly, without EGF treatment, p300 is unable to associate with the cox-2 promoter (Figure 8A, compare lanes 7 with 8). The results indicated that EGF increased the binding of p300 and NF-IL6beta but reduced the binding of SUMO1-modified proteins on the A region of cox-2 promoter.
###end p 49
###begin p 50
###xml 256 265 247 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8B</xref>
###xml 589 594 568 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
Since EGF decreased sumoylation and increased acetylation of NF-IL6beta in A431 cells, we then studied whether suNF-IL6beta lost its ability to interact with p300. Using western blotting assay, we demonstrated that p300 could not bind to the suNF-IL6beta (Figure 8B, compare lanes 3 and 4 with lanes 7 and 8). This result suggested that non-sumoylated or de-sumoylated NF-IL6beta is available for the recruitment of p300 and support our hypothesis that suNF-IL6beta mediates transcriptional inactivation, while p300 and NF-IL6beta/acNF-IL6beta could mediates transcriptional activation of cox-2 gene.
###end p 50
###begin title 51
DISCUSSION
###end title 51
###begin p 52
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">46</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">49</xref>
###xml 239 244 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 585 590 585 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">50</xref>
###xml 703 707 703 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAPK</sup>
###xml 778 780 775 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 792 796 789 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAPK</sup>
###xml 816 821 813 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 908 912 905 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAPK</sup>
###xml 942 947 936 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 617 622 <span type="species:ncbi:9606">human</span>
A number of recent reports described a role of MAPKs signaling in the induction of cox-2 gene in several cell types (46-49). In A431 cells, we demonstrated that U0126, a MEK1 inhibitor, and SP600125, a JNK inhibitor, repressed EGF-induced cox-2 transcription (5). Multiple cell signaling pathways including Src- focal adhesion kinase (FAK), PI3-K, p70S6 kinase, and MAPKs (p38 and ERK1/2) are involved in type I collagen-induced activation of C/EBP and CREB in serum-stimulated macrophages (12). Pharmacological inhibition of PI3-K, ERK1/2 activation, and p38 MAPK activity suppressed cox-2 induction by EGF in CaSki human cervical cancer cell line (50). Our previous study also indicated that PI3-K/p38MAPK pathways mediate EGF-regulated NF-IL6beta transcriptional activation (37). Thus, p38MAPK contributes to the cox-2 transcriptional activation was verified, and we also provide a possible linkage of p38MAPK/NF-IL6beta pathway regulated cox-2 transcription in A431 cells.
###end p 52
###begin p 53
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 110 111 110 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">50</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">53</xref>
###xml 185 190 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">41</xref>
###xml 326 331 326 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">46</xref>
###xml 588 593 585 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 717 719 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 720 722 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 817 822 807 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 838 846 828 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 886 895 876 885 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATTTCGTCA</underline>
###xml 1011 1019 1001 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1092 1097 1079 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1108 1117 1095 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5C</xref>
###xml 1189 1198 1173 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3D</xref>
###xml 1318 1323 1298 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1330 1332 1310 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">54</xref>
###xml 1432 1437 1409 1414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1448 1457 1425 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3C</xref>
###xml 1576 1581 1550 1555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1609 1618 1583 1592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2E</xref>
###xml 1788 1793 1756 1761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1908 1917 1876 1885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4B</xref>
###xml 2098 2107 2063 2072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4A</xref>
###xml 2138 2143 2103 2108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 2198 2207 2163 2172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4B</xref>
###xml 2265 2270 2230 2235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 2475 2477 2437 2439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 2584 2589 2543 2548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 811 816 <span type="species:ncbi:9606">human</span>
CREB and AP-1 (c-Jun/c-Fos) have been reported to bind to the CRE cis-acting element in human cox-2 promoter (5,50-53). We previously demonstrated that c-Jun is involved in EGF-induced cox-2 transcription through transactivation of CRE binding site in A431 cells (5,41). AP-1 transcription factor mediates bombesin-stimulated cox-2 expression in intestinal epithelial cells (46), but has not been linked to the modulation of endogenous expression in epithelial cancer cells. In this study, we provided several lines of evidence suggesting that NF-IL6beta is involved in the regulation of cox-2 by transactivating the CRE site on promoter. The C/EBPs binding consensus sequence is T (T/G)NNGNAA(T/G). Several reports (11-14) have shown that C/EBPbeta or C/EBPdelta could bind to the C/EBP motif, CTTACGCAATG, of human cox-2 promoter using in vitro-binding assay. However, the CRE motif, ATTTCGTCACATG, is also a putative C/EBPs-like motif (the underlined sequence). By gel-shift assay, we found that purified or in vitro-translated NF-IL6beta could directly bind to the C/EBP and CRE motif on cox-2 promoter (Figure 5C) and EGF treatment enhanced the binding of NF-IL6beta to the CRE site (Figure 3D). The same phenomenon of C/EBPdelta binding to the C/EBP and CRE sites was also observed in the LPS- and TPA-regulated cox-2 gene (54). Moreover, overexpression of NF-IL6beta transactivated not only C/EBP motif but also CRE motif on cox-2 promoter (Figure 3C) and cotransfection of cells with c-Jun and NF-IL6beta expression vectors resulted in a synergistic activation of the cox-2 promoter bearing CRE site (Figure 2E). These results support the notion that NF-IL6beta-bound C/EBP motif coordinates with the CRE motif transactivated by NF-IL6beta and c-Jun in the promoter activation of cox-2 gene upon by EGF treatment. EGF activated heterologous pGL2 promoter-C/EBP reporter activity about 4- to 5-folds (Figure 4B), suggesting that C/EBP motif is responsive to EGF stimulation. Activation of the basal transcription activity by overexpression of NF-IL6beta was observed using pXC918 (-918/+49)(Figure 4A, lane 3), -207/+49wt (JM Wang et al., unpublished data) and C/EBP-heterologous reporters (Figure 4B, lane 9). However, EGF could not obviously enhance these cox-2 reporter activities, suggesting that the overexpressed NF-IL6beta may have enough ability to directly recruit the cofactors and create a more intact transcription initiation complex, such as CBP or p300 (31), to mimic EGF stimulation. These results suggested that NF-IL6beta plays a role at the switch control in cox-2 transcriptionalregulation.
###end p 53
###begin p 54
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">55</xref>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 177 185 177 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4</xref>
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">56</xref>
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 445 450 445 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 596 601 593 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 631 636 628 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 639 641 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 889 894 879 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1042 1051 1029 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5B</xref>
###xml 1056 1058 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">6A</xref>
###xml 1231 1246 1212 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5C and D</xref>
###xml 1331 1340 1309 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6C</xref>
###xml 1563 1568 1538 1543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1579 1588 1554 1563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6C</xref>
###xml 1966 1967 1941 1942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 1998 2003 1973 1978 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 2097 2098 2072 2073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 2270 2275 2242 2247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1863 1866 <span type="species:ncbi:9860">Elk</span>
###xml 1946 1949 <span type="species:ncbi:9860">Elk</span>
In resting cells, a low-level of mRNA expression and SUMO-mediated suppression of the promoter have been reported (27,28,55). Sumoylation plays a role in cox-2 gene expression (Figure 4). Several possible regulating proteins have been proposed for the transcription regulation of cox-2 gene, such as histone H4 (56), C/EBPs (5) and p300 (5,38). However, nobody has yet examined the transient change between basal level and ligand-stimulation of cox-2 gene expression. Our study focuses on a novel NF-IL6beta-regulated pathway, involving post-translational modification of the protein to regulate cox-2 transcription. Recently, Kim et al. (25) reported the inhibitory function of C/EBPs by Gal4 fusion protein assay system and showed that lysine 120 was a potential SUMO-conjugated site on C/EBPdelta. Therefore, we demonstrated NF-IL6beta is a SUMO1 and HAT substrate and can regulate the cox-2 transcriptional regulation. We introduced the same point mutation into NF-IL6beta and confirmed that lysine 120 was likely a SUMO-conjugated site (Figure 5B and 6A). The K120A mutant of NF-IL6beta retained the same DNA binding activity, homodimerization activity, protein stability and nuclear localization as the wild-type NF-IL6beta (Figure 5C and D). However, comparing with NF-IL6betawt, it enhanced the transcriptional activation (Figure 6C) suggesting that the post-translational modification might be involved in the modulation of critical protein-protein interaction. Although our reporter assay suggested that suNF-IL6beta plays a repressive function role on cox-2 promoter (Figure 6C), we did not rule out the possibility that other SUMO-modified proteins might be involved in the maintenance of the state of repression. Several SUMO-regulated transcription factors could interact with various HDACs resulting in gene repression. For example, sumoylation of Elk-1 results in the recruitment of HDAC-2 and hence transcriptional repression at Elk-1 target genes (4). HDAC1 decreases LPS-induced cox-2 gene expression had been reported, although the mechanism of recruitment is still not clear (4). Our preliminary results from the DNA affinity precipitation assay demonstrated that suNF-IL6beta could increase the interaction with some HDACs including HDAC1 (JM Wang et al., unpublished data.) These results suggest that suNF-IL6beta has the ability to recruit HDACs to regulate gene expression.
###end p 54
###begin p 55
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57">57</xref>
###xml 238 243 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 259 261 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 336 341 333 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 361 362 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 560 562 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b58">58</xref>
###xml 563 565 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b59">59</xref>
###xml 690 692 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b60">60</xref>
###xml 776 781 763 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 801 810 788 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7D</xref>
###xml 880 888 864 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 890 899 874 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7B</xref>
###xml 944 951 925 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 953 962 934 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7A</xref>
###xml 1097 1099 1075 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b61">61</xref>
###xml 1106 1113 1084 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1443 1448 1412 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1593 1598 1562 1567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1653 1658 1622 1627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1717 1726 1683 1692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8A</xref>
###xml 1806 1814 1769 1777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1830 1839 1793 1802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Figure 8B</xref>
###xml 1979 1984 1936 1941 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 2086 2091 2043 2048 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 2134 2136 2088 2090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b62">62</xref>
###xml 2350 2355 2301 2306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 2721 2723 2666 2668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 2726 2734 2671 2679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 2807 2816 2749 2758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7B</xref>
###xml 2948 2950 2887 2889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b63">63</xref>
###xml 3114 3119 <span type="species:ncbi:10090">mouse</span>
###xml 3143 3148 <span type="species:ncbi:9606">human</span>
###xml 3174 3179 <span type="species:ncbi:10090">mouse</span>
p300 acts as a coactivator for many transcription activators to modulate basal- and enhancer-regulated transcriptional activation (57). C/EBPbeta binding and p300 recruitment are required for phorbol 12-myristate 13-acetate (PMA)-induced cox-2 transcription (38). We previously reported that p300 plays a functional role in EGF-induced cox-2 promoter activity (5). Transcriptional activation by C/EBPalpha and C/EBPbeta coordinated the coactivators, CBP and p300, which promote transcription by acetylating histones and recruiting basal transcription factors (58,59). p300/CBP acetylates the histone tails of nucleosomes, thus favoring chromatin remodeling and activation of transcription (60). In this study, exogenously expressed p300 could increase the NF-IL6beta-mediated cox-2 promoter activity (Figure 7D). We also demonstrated that p300 could directly acetylate NF-IL6beta in vitro (Figure 7B) and EGF enhances acetylation of NF-IL6beta in vivo (Figure 7A). The most interesting thing is lysine 120 of NF-IL6beta can be a sumoylation or acetylation site. The same phenomenon occurs in Sp3 (61). The in vivo studies of something site capable of being both sumoylated and acetylated are difficult to carry out. Nevertheless, it can explain why the repression and activation effect of NF-IL6betaK120A is not obvious. In addition, our experiments in this paper suggest that p300 and NF-IL6beta/AcNF-IL6beta were involved in the EGF-induced cox-2 transcription. This covalent modification might further enhance the architectural stability of the whole general basal transcription factors on cox-2 promoter. By ChIP assays, we showed that EGF enhanced cox-2 promoter binding activities of both p300 and NF-IL6beta. (Figure 8A). The inability of suNF-IL6beta to interact with p300 was also demonstrated by in vitro-binding assay (Figure 8B). Taken together, these results indicate that suNF-IL6beta and acNF-IL6beta are involved, respectively, in the silencing and activation of cox-2 transcription. The dynamic pattern of histone H4 acetylation has been demonstrated to associate with cox-2 transcription by bradykinin and IL-1beta (62). Thus, different acetylation patterns of histones, in conjunction with acNF-IL6beta or other modulators, may result in conformational changes of chromatin and selective association of transcription factor to the cox-2 promoter. We provided evidence to support that NF-IL6beta is a sumoylated protein and also acetylated by EGF treatment in A431 cells. It brings us to deliberate the interplay between the post-translational modification and ligands-induction of NF-IL6beta in downstream target genes. C/EBP proteins could be modified by SUMO-1 attachment within their RDM sequences (25). In vitro-acetylation assay shown NF-IL6beta at least have two acetylation sites (Figure 7B). The RDM sequences of C/EBP proteins exist in the related region. Moreover, C/EBPbeta was identified to be an acetylated protein (63). The similar phenomenon of acetylation site of C/EBPbeta occurs nearby to its DNA binding domain. Align and compare the lysine residues in NF-IL6beta-lysine 184, mouse C/EBPdelta-lysine 184, human C/EBPbeta-lysine 264 and mouse C/EBPbeta-lysine 215, we found these lysine residues close to DNA binding domain are conserved. However, the exact acetylation site on NF-IL6beta and whether the reciprocal action of suNF-IL6beta and acNF-IL6beta is involved in chromatin remodeling needs to be examined.
###end p 55
###begin p 56
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 222 227 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 346 351 340 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 513 518 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 576 581 564 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 599 607 587 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig9">Figure 9</xref>
###xml 683 688 668 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 770 775 752 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1024 1029 997 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1143 1148 1113 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1291 1296 1258 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
In addition to stabilization and de novo synthesis of transcription activators, a gene can also be regulated by post-translational modifications of pre-existing transcription factors. Here, we use the NF-IL6beta-regulated cox-2 system to establish a model that links pre-existing NF-IL6beta and its post-translationally modified form to regulate cox-2 transcription. The present study clearly indicated that NF-IL6beta and its sumoylation and acetylation modifications play a functional role in the regulation of cox-2 promoter. NF-IL6beta regulated the basal and EGF-induced cox-2 gene expression (Figure 9). In resting cells, sumoylation of NF-IL6beta attenuated the activation of cox-2 gene promoter. Upon EGF treatment, the recruitment of p300 and NF-IL6beta to the cox-2 gene promoter is enhanced, while the sumoylated form of NF-IL6beta on gene promoter is attenuated. It suggests that EGF treatment could result in a decrease in SUMO1-modified proteins or suNF-IL6beta, an increase of NF-IL6beta protein bound to the cox-2 promoter and the recruitment of p300 and involvement of NF-IL6beta acetylation activate the promoter activity of cox-2 gene. These results demonstrated a possible interaction between p300 and the post-translational modification of NF-IL6beta in controlling the cox-2 gene expression.
###end p 56
###begin p 57
Thanks are due to Drs Wai-Ming Kan and Rong-Fong Shen for critical review of this manuscript. This work was supported by the Ministry of Education Program for Promoting Academic Excellent of University under the grant number 91-B-FA09-1-4 of Taiwan, Republic of China. Funding to pay the Open Access publication charges for this article was provided by the Ministry of Education.
###end p 57
###begin p 58
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 58
###begin title 59
REFERENCES
###end title 59
###begin article-title 60
Prostaglandin synthase 2
###end article-title 60
###begin article-title 61
Differences in signaling pathways by IL-1beta and IL-18
###end article-title 61
###begin article-title 62
Temporal control of NF-kappaB activation by ERK differentially regulates interleukin-1beta-induced gene expression
###end article-title 62
###begin article-title 63
Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation
###end article-title 63
###begin article-title 64
###xml 129 134 <span type="species:ncbi:9606">human</span>
Essential role of c-Jun induction and coactivator p300 in epidermal growth factor-induced gene expression of cyclooxygenase-2 in human epidermoid carcinoma A431 cells
###end article-title 64
###begin article-title 65
Potentiation of lipopolysaccharide-inducible cyclooxygenase 2 expression by C2-ceramide via c-Jun N-terminal kinase-mediated activation of CCAAT/enhancer binding protein beta in macrophages
###end article-title 65
###begin article-title 66
Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells
###end article-title 66
###begin article-title 67
###xml 109 115 <span type="species:ncbi:10090">murine</span>
Ligand-induced prostaglandin synthesis requires expression of the TIS10/PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages
###end article-title 67
###begin article-title 68
Prostaglandin synthase 1 and prostaglandin synthase 2 both participate in activation-induced prostaglandin D2 production in mast cells
###end article-title 68
###begin article-title 69
###xml 80 85 <span type="species:ncbi:9606">human</span>
Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene
###end article-title 69
###begin article-title 70
Inhibition of lipopolysaccharide-inducible nitric oxide synthase, TNF-alpha and COX-2 expression by sauchinone effects on I-kappaBalpha phosphorylation, C/EBP and AP-1 activation
###end article-title 70
###begin article-title 71
###xml 33 39 <span type="species:ncbi:9913">bovine</span>
Induction of cyclooxygenase-2 by bovine type I collagen in macrophages via C/EBP and CREB activation by multiple cell signaling pathways
###end article-title 71
###begin article-title 72
###xml 33 38 <span type="species:ncbi:9606">human</span>
Induction of cyclooxygenase-2 in human endometrial stromal cells by malignant endometrial epithelial cells: evidence for the involvement of extracellularly regulated kinases and CCAAT/enhancer binding proteins
###end article-title 72
###begin article-title 73
Salicylate suppresses macrophage nitric-oxide synthase-2 and cyclo-oxygenase-2 expression by inhibiting CCAAT/enhancer-binding protein-beta binding via a common signaling pathway
###end article-title 73
###begin article-title 74
###xml 44 49 <span type="species:ncbi:9606">human</span>
Cyclooxygenase-2 induction by bradykinin in human pulmonary artery smooth muscle cells is mediated by the cyclic AMP response element through a novel autocrine loop involving endogenous prostaglandin E2, E-prostanoid 2 (EP2), and EP4 receptors
###end article-title 74
###begin article-title 75
Protein modification by SUMO
###end article-title 75
###begin article-title 76
SUMO and ubiquitin in the nucleus: different functions, similar mechanisms?
###end article-title 76
###begin article-title 77
SUMO, ubiquitin's mysterious cousin
###end article-title 77
###begin article-title 78
Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1)
###end article-title 78
###begin article-title 79
PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies
###end article-title 79
###begin article-title 80
Covalent attachment of the SUMO-1 protein to the negative regulatory domain of the c-Myb transcription factor modifies its stability and transactivation capacity
###end article-title 80
###begin article-title 81
Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies
###end article-title 81
###begin article-title 82
SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization
###end article-title 82
###begin article-title 83
c-Jun and p53 activity is modulated by SUMO-1 modification
###end article-title 83
###begin article-title 84
Transcriptional activity of CCAAT/enhancer-binding proteins is controlled by a conserved inhibitory domain that is a target for sumoylation
###end article-title 84
###begin article-title 85
Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity
###end article-title 85
###begin article-title 86
Modification with SUMO
###end article-title 86
###begin article-title 87
Modification of CCAAT/enhancer-binding protein-beta by the small ubiquitin-like modifier (SUMO) family members, SUMO-2 and SUMO-3
###end article-title 87
###begin article-title 88
Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and -independent mechanisms
###end article-title 88
###begin article-title 89
Interaction and functional collaboration of p300 and C/EBPbeta
###end article-title 89
###begin article-title 90
CCAAT/enhancer-binding protein family members recruit the coactivator CREB-binding protein and trigger its phosphorylation
###end article-title 90
###begin article-title 91
Insulin suppresses transactivation by CAAT/enhancer-binding proteins beta (C/EBPbeta). Signaling to p300/CREB-binding protein by protein kinase B disrupts interaction with the major activation domain of C/EBPbeta
###end article-title 91
###begin article-title 92
Recruitment of p300 by C/EBPbeta triggers phosphorylation of p300 and modulates coactivator activity
###end article-title 92
###begin article-title 93
Critical role of C/EBPdelta and C/EBPbeta factors in the stimulation of the cyclooxygenase-2 gene transcription by interleukin-1beta in articular chondrocytes
###end article-title 93
###begin article-title 94
Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages
###end article-title 94
###begin article-title 95
The induction of cyclooxygenase-2 mRNA in macrophages is biphasic and requires both CCAAT enhancer-binding protein beta (C/EBP beta) and C/EBP delta transcription factors
###end article-title 95
###begin article-title 96
###xml 13 18 <span type="species:ncbi:9606">human</span>
Induction of human NF-IL6beta by epidermal growth factor is mediated through the p38 signaling pathway and CREB activation in A431 cells
###end article-title 96
###begin article-title 97
Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins
###end article-title 97
###begin article-title 98
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei
###end article-title 98
###begin article-title 99
Two waves of nuclear factor kappaB recruitment to target promoters
###end article-title 99
###begin article-title 100
Activating protein 1-mediated cyclooxygenase-2 expression is independent of N-terminal phosphorylation of c-Jun
###end article-title 100
###begin article-title 101
###xml 61 64 <span type="species:ncbi:9860">Elk</span>
Dynamic Interplay of the SUMO and ERK Pathways in Regulating Elk-1 Transcriptional Activity
###end article-title 101
###begin article-title 102
SUMO modification of STAT1 and its role in PIAS-mediated inhibition of gene activation
###end article-title 102
###begin article-title 103
Transcriptional regulation of the cyclooxygenase-2 gene in macrophages by PU.1
###end article-title 103
###begin article-title 104
p300 coactivates the adipogenic transcription factor CCAAT/enhancer-binding protein alpha
###end article-title 104
###begin article-title 105
Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells
###end article-title 105
###begin article-title 106
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization. An event of early pregnancy
###end article-title 106
###begin article-title 107
###xml 103 108 <span type="species:ncbi:9606">human</span>
Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes
###end article-title 107
###begin article-title 108
Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways
###end article-title 108
###begin article-title 109
###xml 37 42 <span type="species:ncbi:9606">human</span>
Cyclooxygenase-2 is overexpressed in human cervical cancer
###end article-title 109
###begin article-title 110
###xml 93 98 <span type="species:ncbi:9606">human</span>
Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells
###end article-title 110
###begin article-title 111
Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300
###end article-title 111
###begin article-title 112
Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR
###end article-title 112
###begin article-title 113
###xml 30 35 <span type="species:ncbi:9606">human</span>
Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element
###end article-title 113
###begin article-title 114
SUMO promotes HDAC-mediated transcriptional repression
###end article-title 114
###begin article-title 115
Histone sumoylation is associated with transcriptional repression
###end article-title 115
###begin article-title 116
CREB-binding protein and p300 in transcriptional regulation
###end article-title 116
###begin article-title 117
###xml 140 145 <span type="species:ncbi:4932">yeast</span>
CCAAT/enhancer binding protein-alpha amino acid motifs with dual TBP and TFIIB binding ability co-operate to activate transcription in both yeast and mammalian cells
###end article-title 117
###begin article-title 118
A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes
###end article-title 118
###begin article-title 119
A role for cofactor-cofactor and cofactor-histone interactions in targeting p300, SWI/SNF and Mediator for transcription
###end article-title 119
###begin article-title 120
Transcription factor Sp3 is silenced through SUMO modification by PIAS1
###end article-title 120
###begin article-title 121
###xml 86 91 <span type="species:ncbi:9606">human</span>
Transcriptional regulation of cyclooxygenase 2 by bradykinin and interleukin-1beta in human airway smooth muscle cells: involvement of different promoter elements, transcription factors, and histone h4 acetylation
###end article-title 121
###begin article-title 122
STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta
###end article-title 122
###begin title 123
Figures and Tables
###end title 123
###begin p 124
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 233 234 233 234 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 545 555 545 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF-IL6&#946;</italic>
###xml 560 565 557 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
(A) EGF-induced COX-2 expression and C/EBP protein levels in A431 cells. Cell lysates were harvested after EGF treatment. Antibodies to recognize the COX-1, COX-2, c-Jun and C/EBPs protein levels performed by western blot analysis. (B) SB203580, p38 inhibitor, attenuates EGF-induced cox-2 transcription in a dose-dependent manner. A431 cells deprived of serum were pretreated with p38 inhibitor SB203580 for 30 min prior to stimulation with EGF for 90 min. After stimulation, cells were lysed, and total RNA was prepared for RT-PCR analysis of NF-IL6beta and cox-2 mRNA levels.
###end p 124
###begin p 125
###xml 44 49 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 57 58 54 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 102 107 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 205 210 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 448 449 435 436 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 509 514 493 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 590 595 570 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 838 843 811 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 848 858 821 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF-IL6&#946;</italic>
###xml 931 939 901 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Silencer</italic>
###xml 1050 1051 1008 1009 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1390 1391 1324 1325 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1453 1458 1384 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1802 1803 1718 1719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1811 1812 1727 1728 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1877 1882 1790 1795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 2264 2265 2162 2163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
NF-IL6beta plays a role in transcription of cox-2 gene. (A) Overexpression of NF-IL6beta enhances the cox-2 reporter activity. A431 cells were transfected with 0.2 microg of reporter vector pXC80 carrying cox-2 promoter (-80/+49 bp) together with expression vector of NF-IL6beta in 1 ml of Opti-MEM medium. After medium change, cells were treated with or without EGF for 13 h. Cell lysates were then prepared, and luciferase activity was assayed. (B) Silencing of NF-IL6beta expression attenuates EGF-induced cox-2 reporter activity. Cells were transfected with 1 microg of pXC918 carrying cox-2 promoter (-918/+49 bp) together with 1 microg of pSi-C or pSi-I. The upper panel shows that the transfection of NF-IL6beta expression vectors attenuated the pXC918 reporter activity. The lower panel shows that the transcriptional products of cox-2 and NF-IL6beta genes which were examined by RT-PCR analysis. The pSi-C represents the pSilencertrade mark negative control plasmid. The pSi-I indicates the specific NF-IL6beta knockdown expression vector. (C) Reduction of NF-IL6beta expression decrease COX-2 expression. The transfection of pcDNA3/HA-NF-IL6beta with pSi-C or pSi-I was performed in HeLa cells. Cellular lysates were harvested and analysed by western blotting probed with alpha-HA, alpha-COX-2 and alpha-beta-actin antibodies. beta-Actin was used as an internal loading control. (D) Silencing of c-Jun expression attenuates NF-IL6beta-induced cox-2 reporter activity. A431 cells were transfected with 0.2 microg of pXC80, together with 0.5 microg of expression vector pSUPERc-Jun siRNA and 0.2 microg of each expression vector of c-Jun and NF-IL6beta in 1 ml of Opti-MEM medium. Statistical significance between pSUPERc-Jun siRNA-transfected and untransfected cells was analysed by Student's t-test. (E) Cooperation of NF-IL6beta with c-Jun in promoter activation of cox-2 gene. A431 cells were transfected with 0.2 microg of pXC80 reporter vector together with 0.05 microg of expression vector of NF/IL6beta and 0.02 microg of expression vector of c-Jun in 1 ml of Opti-MEM medium. Cell lysates were then prepared, and luciferase activity was assayed. Statistical significance between c-Jun-transfected and untransfected cells was analysed by Student's t-test.
###end p 125
###begin p 126
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 95 96 95 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 233 234 233 234 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 279 284 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 402 407 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 808 809 804 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 817 818 813 814 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 863 868 859 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 1437 1438 1423 1424 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
C/EBP and CRE motifs play functional role in EGF-induced cox-2 gene activation in A431 cells. (A) Schematic representation of constructs used in this study. The mutated sequences in each individual construct are shown in lowercase. (B) The C/EBP and CRE motifs are important for cox-2 gene activation. A431 cells transfected with 2 microg of indicated reporters containing site-directed mutagenesis of cox-2 promoter were treated with (black column) or without (white column) EGF for 16 h (right panel). Cell lysates were then prepared, and luciferase activity was assayed. Each group was performed with triplicate assays. In the left panel, three independent assays were performed, and the relative EGF inducibility to wild and mutant promoters was compared. Statistical analysis was performed by Student's t-test. (C) Both CRE and C/EBP motifs are important on cox-2 promoter activity. A431 cells, transfected with 1 microg of indicated reporters together with an expression vector encoding NF-IL6beta or an empty vector, were left in medium without EGF treatment for 16 h. Cell lysates were prepared, and luciferase activity was assayed. The graph shown is a relative result. Ratio between the luciferase activity of each reporter cotransfected with NF-IL6beta expression vector and that cotransfected with empty vector was calculated, and then normalized by assigning the relative luciferase ratio of -207/+49wt to a value of 100%. (D) NF-IL6beta binds to the C/EBP and CRE elements in DNA affinity precipitation assay. Nuclear extracts were harvested from cells treated with EGF and incubated with biotin-labeled oligonucleotides. The precipitated products pulled down by streptavidin-Sepharose were analysed by western blotting with alpha-C/EBPdelta antibodies.
###end p 126
###begin p 127
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 134 135 130 131 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 176 177 172 173 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Sumoylation plays a negative regulation role in cox-2 promoter. Cells transfected with 1 microg of pXC918 luciferase reporter vector (A) or C/EBP-heterologous reporter vector (B) together with 0.5 microg of indicated expression vector were treated with or without EGF for 16 h. Cell lysates were performed, and luciferase activity was assayed. Each group was performed with triplicate assays.
###end p 127
###begin p 128
###xml 48 49 45 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 93 101 87 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 103 111 97 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 136 144 130 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 339 340 326 327 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 401 409 385 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 539 540 519 520 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 614 616 591 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 664 672 641 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 760 761 731 732 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
NF-IL6beta is a target for attachment of SUMO. (A) NF-IL6beta is a SUMO1 and SUMO3 substrate in vitro. In vitro-sumoylation assay using in vitro-translated HA/NF-IL6beta and SUMO1 or SUMO3 protein were performed as described in Materials and Methods. The reaction mixtures were separated by SDS-PAGE and blotted with alpha-HA antibodies. (B) Lysine120 (K120) of NF-IL6beta is a SUMO1-conjugated site. In vitro-sumoylation assay was performed as in A. The reaction mixtures were separated by SDS-PAGE and blotted with alpha-HA antibodies. (C) suNF-IL6beta does not affect DNA-binding activity. Gel-shift assay with 32P-labeled C/EBP or CRE probes and equal mass of in vitro-translated NF-IL6beta (lanes 2 and 6), or suNF-IL6beta (lanes 3 and 6) was performed. (D) K120A mutant has the same protein turnover rate with wild-type NF-IL6beta. Cells transfected with 0.5 microg of expression vector of HA/NF-IL6betawt or HA/NF-IL6betaK120A were treated with or without EGF in the presence of 10 microg/ml cycloheximide. Cell lysates were then prepared, and the immunoblotting was performed using alpha-HA antibodies. The graph was plotted by normalizing the level of HA/NF-IL6beta or HA/NF-IL6betaK120A at each time point, and each protein level at time zero point was assigned to a value of 100%.
###end p 128
###begin p 129
###xml 40 41 37 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 66 73 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 317 318 300 301 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 760 761 733 734 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 789 794 759 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
EGF attenuates NF-IL6beta sumoylation. (A) NF-IL6beta sumoylation in vivo. Cell lysates were prepared from A431 cells transfected with 1 microg of each indicated expression vector, and the western blotting was performed with alpha-HA antibodies. Arrow sign represents the position of suHA/NF-IL6beta (lanes 3 or 4). (B) EGF attenuates HA/NF-IL6beta sumoylation in A431 cells. Cells transfected with expression vectors as indicated were treated with or without EGF. Cell lysates were then prepared, and immunoprecipitated with specific SUMO1 antibodies. The immunoprecipitated products were analysed by alpha-HA antibodies and quantified with densitometer. The 'Input' represents the lysates containing exogenous HA/NF-IL6beta before immunoprecipitation step. (C) NF-IL6betaK120A increased cox-2 reporter activity. Cells transfected with plasmid 0.5 microg of -207/+49wt together with 0.1 or 0.5 microg of each expression vectors as indicated were treated with or without EGF. Cell lysates were then prepared, and luciferase activity was assayed.
###end p 129
###begin p 130
###xml 39 40 36 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 91 98 85 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 367 368 353 354 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 417 425 397 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 427 435 407 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 573 574 547 548 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 647 652 615 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 919 920 879 880 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1285 1286 1234 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
NF-IL6beta is a HAT (p300) substrate. (A) EGF stimulation increases NF-IL6beta acetylation in vivo. The lysates, prepared from cells transfected with 1 microg of each indicated expression vector with or without EGF treatment, were immunoprecipitated with specific anti-acetyl-lysine antibodies. The immunoprecipitation products were analysed by alpha-HA antibodies. (B) p300 acetylates NF-IL6beta and NF-IL6betaK120A in vitro. In vitro-acetylation assay using purified p300 protein and His/NF-IL6beta or His/NF-IL6beta was performed as described in Materials and Methods. (C) Silencing of NF-IL6beta expression attenuates p300/NF-IL6beta-enhanced cox-2 promoter activity. Cells transfected with 0.5 microg of reporter plasmid -207/+49wt together with 0.5 microg of each expression vector as indicated were left in medium without EGF treatment for 16 h. Cell lysates were prepared, and luciferase activity was assayed. (D) Overexpression of p300 increases NF-IL6beta-induced -207/+49wt reporter activity. Cells transfected with 0.5 microg of reporter plasmid -207/+49wt together with 0.5 microg of each expression vector as indicated were left in medium without EGF treatment for 16 h. Three independent experiments were performed, and the statistic analysis was performed by Student's t-test.
###end p 130
###begin p 131
###xml 24 29 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 44 51 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 54 55 51 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 186 191 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 369 374 366 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 414 415 411 412 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 568 576 562 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 720 728 711 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 840 848 831 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 880 888 871 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
NF-IL6beta binds to the cox-2 gene promoter in vivo. (A) ChIP analysis was performed as described in Materials and Methods. The upper panel indicates the scheme of 5'-flanking region of cox-2 gene, and the location of designed primers for PCR. Chromatin from A431 cells with or without EGF treatment was immunoprecipitated with specific antibodies as indicated and the cox-2 promoter region was amplified by PCR. (B) Purified p300 proteins cannot interact with suNF-IL6beta. The pull-down assay was performed using the mixtures of purified p300 protein incubated with in vitro-translated HA/NF-IL6beta with or without sumoylation enzymes as described in Materials and Methods. The 'C' represents the control products of in vitro transcription/translation reaction with pCDNA3/HA vector; the 'Su-C' represents the products were performed by in vitro-translated control products in in vitro-sumoylation reaction. Western blots of reaction mixture (left panel) and alpha-p300-immunoprecipitated pellet (right panel), using alpha-HA antibodies, are indicated.
###end p 131
###begin p 132
###xml 40 45 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
###xml 171 176 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cox-2</italic>
NF-IL6beta is a bifunctional protein in cox-2 transcription. In the resting cell stage, suNF-IL6beta recruits HDACs to play a repressor role and result in inactivation of cox-2 transcription. Presence of EGF, p300 could bind to NF-IL6beta. Once recruited, p300 can acetylate NF-IL6beta, cooperate with NF-IL6beta/c-Jun complex and result in conformational changes of chromatin to form a more stable transcription initiation complex.
###end p 132

